REGULATORY

Chuikyo OKs Outline of FY2016 Drug Pricing Reform

December 25, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) on December 25 approved the outline of the FY2016 drug pricing reform next April, opening the way for the introduction of a special re-pricing rule for “huge seller” drugs and a new rule…

To read the full story

JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
January 5, 2016
Re-Pricing of Huge Seller Drugs “Extremely Unreasonable”: FPMAJ
January 5, 2016
Gist of FY2016 Drug Pricing Reform
December 25, 2015

REGULATORY

Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…